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Background:Tau is hyperphosphorylated in the tauopathies. Targeting Tau kinases CDK5 and GSK3 represents a poten-
tial therapeutic approach.
Results: Inhibitors of Tau kinases are neuroprotective, decrease PHF-1 immunoreactivity, and induce recovery of memory by
fear conditioning.
Conclusion: Diaminothiazoles as CDK5 and GSK3 inhibitors improve the tauopathy in mouse models.
Significance: Dual kinase inhibition can be critical for efficacy when treating tauopathies.
Although Tau accumulation is a feature of several neurode-
generative conditions, treatment options for these conditions
are nonexistent. Targeting Tau kinases represents a potential
therapeutic approach. Small molecules in the diaminothiazole
class are potent Tau kinase inhibitors that target CDK5 and
GSK3. Lead compounds from the series have IC50 values
toward CDK5/p25 and GSK3 in the low nanomolar range and
no observed toxicity in the therapeutic dose range. Neuronal
protective effects and decreased PHF-1 immunoreactivity were
observed in two animal models, 3Tg-AD and CK-p25. Treat-
ment nearly eliminated Sarkosyl-insoluble Tau with the most
prominent effect on the phosphorylation at Ser-404. Treatment
also induced the recovery of memory in a fear conditioning
assay. Given the contribution of both CDK5/p25 and GSK3 to
Tau phosphorylation, effective treatment of tauopathies may
require dual kinase targeting.
The brains of patientswithAlzheimer disease (AD)4 undergo
extensive cell death and are histopathologically characterized
by both plaques containing amyloid- protein and neurofibril-
lary tangles (NFTs) containing hyperphosphorylated Tau pro-
tein. Therapeutic strategies directed toward the NFTs are few
and remain unproven. They include inhibition of Tau aggrega-
tion with methylene blue (1), passive Tau immunotherapy (2),
microtubule stabilization (3), and inhibition of Tau kinases
such as glycogen synthase kinase 3 (GSK3) and cyclin-de-
pendent kinase 5 (CDK5) (4–6). As a candidate target for
tauopathies, CDK5 has the merit of phosphorylating Tau at
NFT-associated residues. In vitro studies with peptide sub-
strates indicated that a (Ser/Thr)-Promotif directsCDK5phos-
phorylation without previous phosphorylation of the substrate
being required (7). Both in vitro Tau phosphorylation and in
vivo transgenic mouse studies showed that CDK5 is involved in
abnormal Tau phosphorylation at residues typically found
phosphorylated in insoluble paired helical filament (PHF) Tau.
These residues include Ser-202/Thr-205, Thr-231/Ser-235,
and Ser-396/Ser-400/Ser-404 (8–10). Many of these sites can
also be phosphorylated by GSK3 (11). However, GSK3 is
primarily known to recognize specifically (Ser/Thr)-Pro-Xaa-
Xaa-(Ser(P)) motifs, once Ser(P) has been phosphorylated by
another kinase, such as CDK5. Support for developing CDK5
inhibitors also stems from its fairly specific neuronal activity
due to the restricted neuronal expression of its activators p35
and p39 (12, 13). Various neuronal insults, such as oxidative
stress and A peptides, can cause calpain-induced cleavage of
the CDK5 activator p35 to p25 (14). As a result, themembrane-
targeting sequence of p35 is lost, and the CDK5-p25 complex
becomes mislocalized to the cytoplasm. CDK5/p25 can induce
NFTs when overexpressed in the CK-p25 mouse model, which
displays distinctive neuronal loss after 6 weeks of induction
preceding NFT formation (9). Also, specific inhibition of
CDK5/p25 activity by overexpression of CDK5 inhibitory pep-
tide reduced neurodegeneration in vivo (15). Furthermore,
when CDK5 was knocked down by RNAi in the triple trans-
genic AD (3Tg-AD) mouse model, NFTs were reduced (16).
This model combines the expression of APPswe, PSN1M146v/,
and human P301L Tau to present an AD-like pathology that
includes both A plaque and NFT formation (17). Previously,
we identified the small molecule diaminothiazole as a CDK5
inhibitor from high throughput screening (HTS) (18). A few
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compounds from this series emerged from structure-activity
relationship (SAR) studies as having good potency with in vitro
IC50100 nM (19). Here, we report preclinical characterization
of this diaminothiazole series of CDK5 inhibitors. Efficacy in
vivo assays were studied in CK-p25 and 3Tg-ADmousemod-
els. The outcome was measured with respect to the level of
phosphorylated Tau, the formation of NFTs, neuronal survival,
DNA damage, and behavior. Collectively, our experiments
demonstrate the neuroprotective effects of the diaminothiazole
class of CDK5 inhibitor treatment compared with the controls.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents
The following antibody was used: PHF-1 (1:1000; a gift from
Dr. Peter Davies, Albert Einstein College of Medicine). Addi-
tional primary antibodies used included anti-CDK5 (1:500;
Santa Cruz Biotechnology sc-173), anti-phosphorylated Tau
Ser-235 (1:1000; Santa Cruz Biotechnology sc-181012), anti-
Tau5 (1:2000; Abcam ab80579), anti--actin from mouse
(1:1000; Sigma 5441), anti-H2AX phospho-Ser-139 (1:1000;
Abcam ab11174). Alexa 488 goat anti-rabbit IgG1 (1:5000;
Molecular Probes) and Alexa 594 goat anti-mouse IgG1
(1:5000; Molecular Probes) were used as secondary fluorescent
probes in histology tissue. IR-DYE 680 goat anti-mouse IgG1
(1:10,000; Odyssey) and IR-DYE 800 goat anti-rabbit IgG1
(1:5000; Odyssey) were used as secondary fluorescent probes
for Western blots. Horseradish peroxidase-conjugated goat
anti-mouse IgG (1:2000; Santa Cruz Biotechnology, sc2055)
was also used as a secondary antibody.
All chemicals were purchased from Sigma unless specified
otherwise. Polyethylene glycol 400 (PEG 400) was purchased
from Fluka (81172), CellTiter 96 AQueous One Solution Cell
Proliferation Assay was from Promega; protease inhibitor mix-
ture was from Roche Applied Science (11836153001), and
phosphatase inhibitor was from Thermo Scientific (78420).
Compounds
Synthesis of LDN-193594, -193665, and -212853 has been
reported previously as compounds 26, 27, and 44 (19). For
LDN-212828, -213842, and -213843, the diaminothiazoleswere
synthesized using the same approach, while the required iso-
thiocyanateswere prepared. Compound characterization by 1H
NMR is as follows: LDN-213828, 1H NMR (500 MHz, DMSO-
d6)  1.50–1.61 (m, 6H), 3.46–3.48 (m, 4H), 6.81 (d, J 9.0 Hz,
1H), 7.23–7.28 (m, 2H), 7.42–7. 49 (m, 2H), 7.61 (bs, 1H), 8.02–
8.24 (bm, 3H), 10.45 (s, 1H); LDN-213842, 1H NMR (500MHz,
DMSO-d6)  3.38–3.41 (m, 2H), 3.68–3.70 (m, 2H), 6.86 (d, J
11.0 Hz, 1H), 7.23–7.28 (m, 2H), 7.42–7. 49 (m, 2H), 7.71 (bs,
1H), 8.01–8.23 (bm, 3H), 10.52 (s, 1H); LDN-213843, 1H NMR
(400 MHz, DMSO-d6)  3.17–3.19 (m, 2H), 3.65–3.67 (m, 2H),
6.94 (d, J 9.2 Hz, 1H), 7.25–7.30 (m, 2H), 7.43–7. 49 (m, 2H),
7.77 (bs, 1H), 8.12–8.31 (bm, 3H), 10.60 (s, 1H).
In Vitro Experiments
CDK5 kinase activity in vitro assay was performed as
described previously (19). The in vitro radioactive assay of
CDK5 used H1P (histone H1-derived peptide PKTPKKAKKL)
as substrate with buffer containing 20 mM MOPS, pH 7.5, 10
mMMgCl2, 1mMDTT, 0.5mg/ml BSA. IC50 was determined at
40 M H1P, 60 M ATP, and 6.6 nM CDK5/p25 enzyme. The
reactions were conducted in duplicate.
CDK5 kinase activity in primary neuronal culture was evalu-
ated using primary cultured neurons prepared from brain hip-
pocampus of E18 rat fetuses. The inhibition effect of the com-
pounds on Tau phosphorylation represented by EC50 was
evaluated by Western blot with phospho-Tau Ser-235 anti-
body. Anti-CDK5 was used as normalization control.
Cytotoxicity test was performed in primary neuronal culture
on 24-well plates at a density of 80,000 cells/well. LD50 was
measured after 24 h of incubation as described (18) using the
CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega).
Values for cLogP and polar surface areawere calculated using
molinspiration. Aqueous solubility was accessed by turbidity in
1% DMSO/water solution.
Mouse microsomal stability of the compounds was deter-
mined at 10Musing pooledmalemouse livermicrosomes (BD
Biosciences, B6C3F1) following the manufacturer’s protocols.
Briefly, compounds (10M)were incubated (n 2)with pooled
mouse liver microsomes (0.5 mg protein/ml) at 37 °C for 0, 16,
30, 60, 120, and 240min before termination of reactions and the
compound extraction with the same volume of acetonitrile as
the reactionmixture. Samples were centrifuged, and the result-
ant supernatant was analyzed for disappearance of parent com-
pound by LC-UV and LC/MS/MS. The absorption under the
curve was referenced to the zero time point samples (as 100%)
to determine the percentage of compound remaining. The nat-
ural log plots of the percentage remaining for each compound
were used to determine the half-life for the microsomal incu-
bations. Half-life values were calculated from the relationship
t1⁄2 (min)  0.693/, where  was the slope of the natural
logarithm of concentration to the time curve.
Animals
All experimental protocols were approved by the Institu-
tional Animal Care and Use Committee at the University of
California Santa Barbara or Massachusetts Institute of Tech-
nology in accordance with National Institutes of Health guide-
lines. All the triple-transgenic Alzheimer mice (3Tg-AD, 23
months old) (17) used in this study were bred and housed at the
University of California at Santa Barbara animal facility. Adult
(10 weeks old) double-transgenic male CK-p25 (CamkII-tTA-
TetO-p25-eGFP) mice (9) and control littermates were bred
and housed at Massachusetts Institute of Technology. Mice
were constantly kept under a doxycycline-supplemented diet to
keep tetracycline-controlled Transcriptional Activator (tTA)
inactive and block the expression of p25-eGFP. At 10 weeks of
age, mice were switched and maintained on a doxycycline-free
diet to turn on the expression of p25-eGFP for the following 6
weeks. p25 induction only takes place in the double CK-p25
mice carrying the two transgenes. Immunohistology and fear
conditioning were done after this 6-week period of p25 induc-
tion, the timewhen neuronal loss and cognitive deficits are first
visible (20).
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Tissue Collection—Triple transgenic Alzheimer mice
(3Tg-AD)were i.p. injectedwith a single dose of LDN-193594
(120 mg/kg) dissolved in PEG 400/water (40:60, v/v). Animals
were sacrificed 3, 10, 30, 60, 120, 180, and 240 min after injec-
tion. Two animals were used for each time point for pharmaco-
kinetic analysis. Animals were anesthetized with pentobarbital
(Schering-Plough); blood was collected by intracardiac punc-
ture in 1.5-ml tubes containing EDTA, centrifuged 2500 g for
10min at 25 °C followedby 0.9% sterile saline perfusion (Baxter,
USP). Plasma was obtained and stored at80 °C until assayed.
Cortex was dissected from the brain, weighed, and homoge-
nized in 500 l of PBS buffer, pH 7.4, and stored at80 °C.
Sample Preparation and Analytical Methods—Analytical
samples in plasma or brain homogenate were prepared by
precipitation of proteins with 3 volumes of methanol. After
centrifugation, the supernatant was directly submitted to
LC/UV/MS analysis. Standard calibration in plasma or brain
homogenate was done by diluting a series of 10 stock solu-
tions of the compound in PEG400/water (40:60, v/v) into either
plasma or brain homogenates from untreated mouse to a 1
final concentration. Analytical methods were developed by
LC/UV/MS using aWaters 2695HPLCwith a chilled autosam-
pler connected to the Waters 996 photodiode array UV detec-
tor and micromass QTOF2 quadrupole/time-of-Flight tandem
mass spectrometer. After separation on a C18 reverse phase
HPLC column, Kromasil 100-5C18 (4.6  250 mm, 5 m),
using an acetonitrile/water gradient system, peaks were quali-
tatively characterized by mass spectrometry (MS/MS) using
ESI ionization. Standard curves were determined based on
the correlation between the concentration and UV absorp-
tion. The limit of quantification for most of the compounds
tested was found to be less than 0.1 M for both plasma and
brain homogenate.
Data Analysis—A one-compartment model was used to
compute pharmacokinetic values from mean compound con-
centration versus time both for plasma and brain after i.p. injec-
tion. Data were fit to a one-compartment model using the on-
line software SBPKPD. Results are presented as mean S.E. of
two animals for each time point (Fig. 2A). The brain versus
plasma ratio was computed by dividing the brain concentration
by the concurrent plasma concentration at each time point.
Ex Vivo CDK5 Kinase Assay
The assay was performed by a modified procedure described
previously (16). CD1 mice (Charles River Laboratories) were
euthanized 15 min after i.p. injection of LDN-193594 in 40%
PEG or 40% PEG alone. According to the pharmacokinetic pro-
file, compound LDN-193594 in the cortex reached Cmax of 69
M 10 min after i.p. injection. The cortex was then dissected
and placed on a 1.5-ml microcentrifuge tube containing lysis
buffer with protease inhibitor and phosphatase inhibitor. The
tissue was homogenized, incubated for 15 min on ice, and cen-
trifuged at 13,000 rpm at 4 °C. Supernatant was recovered in
clean microcentrifuge tubes, and protein concentration was
measured with the bicinchoninic acid method. CDK5 was
immunoprecipitated from 250 g of total protein using 1 g of
IgG rabbit polyclonal anti-CDK5 (C-8) antibody. IgG isotype
immunoprecipitation was used as negative control and done in
a parallel fashion. Antibody and protein extract were incubated
overnight at 4 °C in a rotator; protein G-Sepharose was added
and incubated for an additional 1 h at 23 °C, and proteinG-Sep-
harose beads were washed five times with immunoprecipita-
tion (IP) buffer at 4 °C. After the fifth wash, the protein G-Sep-
harose beads were resuspended in kinase assay buffer (20 mM
MOPS, pH 7.4, 50 mMNaCl, 0.1 mM EDTA, 1 mMDTT, 10 mM
MgCl2), and H1 peptide was added as a substrate for CDK5 at a
final concentration of 500 M. Reaction was initiated by 4 Ci
of [-32P]ATP at a final concentration of 500 M. The reaction
mixture was incubated at 37 °C and was quenched with 5 l of
acetic acid for every 20 l of reaction mixture at 10, 30, and 60
min. The phosphorylated H1 peptide product was separated
from excess ATP by P81 cation-exchange chromatography on
phosphocellulose paper using 0.1% phosphoric acid as develop-
ing solution. After complete drying at room temperature, the
radioactivity of phosphorylated H1 peptide was detected by a
phosphorimager and later read by a scintillation counter. For
the kinase activity assay, recombinant CDK5/p25 was used as
positive control, although protein fraction of IgG isotype
immunoprecipitation was used as negative control. Reaction
rate was calculated as the linear rate of the phosphorylated H1
peptide formation over time (M/min).
Toxicity
3Tg-AD (23 months old) mice were injected daily i.p. with
PBS, vehicle (40–60%PEG400), kinase inhibitors LDN-193594
(30, 60, and 120mg/kg/day), or LDN-213828 (39 and 78mg/kg/
day). Mice were monitored for a week to determine symptoms
of pain or distress, and the weight was recorded daily.
Efficacy Study
Intracerebroventricular (i.c.v.) Infusion with Ck-p25 Mouse—
In the CK-p25 mouse model, the compound LDN-193594 was
first delivered by i.c.v. infusion throughout the entire induction
time to maximize the drug efficacy inhibiting the hyperactiva-
tion associated with p25-eGFP overexpression (Table 1, exper-
iments 1 and 2), and the protocolwas applied to LDN-213828 in
experiment 3. Six-week Alzet pumps (model 2006, Alzet
osmotic pumps) were filled with excipient or the experimental
compound in excipient at a concentration to ensure a diffusion
of 100 nmol of compound per day. Pumpswere connected to an
i.c.v. plunger (brain infusion kit III, Alzet osmotic pumps)
through a 2-cm tube connector previously filled with the same
solution. Once assembled, pumps were kept for 2 h at 37 °C in
sterile saline to allow pump priming. Mice were anesthetized
using a mixture of ketamine/xylazine/buprenex (100:10:0.1
mg/kg, respectively) and placed in a stereotaxic apparatus
(Kopf Instruments). Pumps were placed in the inter-shoulder
blade area, and the i.c.v. plunger was lowered through a surgi-
cally drilled hole in the skull to allow the placement of the
plunger cannula tip at the following coordinates: anterior-pos-
terior  0.46, lateral 1.25 mm from Bregma, and dorsal
2.25 mm from the skull surface. Those coordinates allowed
infusion of the drug in the i.c.v. space. Once the plunger was
lowered to the half-distance, surgical glue was applied around
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its base (Loctite 454, Alzet osmotic pumps) and then lowered to
its final position, which ensured a tight fit against the skull
surface.
Subcutaneous/Intraperitoneal (s.c./i.p.) Experiment—CK-
p25 mice and control littermates with p25 induced for 3 weeks
were treated with a combination of s.c. and i.p. drug delivery; at
first,micewere subcutaneously implantedwith 2-week osmotic
pumps (Alzet, model 2004) filled with a solution of excipient or
compound in excipient so mice would receive a treatment for 2
weeks at 1dose. Then, for the lastweek of p25 induction,mice
received daily i.p. delivery of the same solution at 2 dose.Mice
were then sacrificed, and the effect of the treatment on neuron
loss and Tau phosphorylation was evaluated. CK-p25 mice
already induced for 3 weeks were treatedwith s.c. infusion of 30
mg/kg/day in the following 2 weeks and with a daily i.p. injec-
tion of 60 mg/kg during the 6th week of p25 overexpression
(experiment 4). We did not analyze the concentration reached
in the brain following this treatment but noticed some of the
compound had precipitated in the area around the pump
implantation site. This slight precipitation seemed to indicate
that Cmax in the infusion delivery was reached and that
prompted us to combine this treatment with daily i.p. injec-
tions, which allowed a larger volume and higher concentration
for drug administration, during the last week of treatment.
LDN-213828 was delivered according to the same protocol
(experiment 5). Based on its molecular weight, the doses were
39 and 78 mg/kg/day s.c. and i.p., respectively. We chose to
treat the 3Tg-AD daily for 1 week via i.p. injection with com-
pound LDN-193594 in two doses (30 and 60 mg/kg/day)
(experiments 6 and 7). The same protocol was applied to com-
pound LDN-213828 in experiments 8 and 9. Finally, we deliv-
ered compound LDN-193594 at 60 mg/kg/day by s.c. injection
in experiment 10. After treatment, all mice were anesthetized,
followed by intracardiac perfusion with 0.9% sterile saline solu-
tion (Baxter, USP). The brain was removed and hemilaterally
excised. The left hemisphere was subsequently used for immu-
nofluorescence, whereas the right hemisphere was used for
immunoblotting.
Behavior
As described previously (20), fear conditioning was con-
ducted using 6-weekCK-p25-inducedmice or single transgenic
control littermates treated with s.c./i.p. treatment with either
LDN-193594 or vehicle during the last 3 weeks of induction.
The observer was blinded to the genotype and type of treat-
ment. Mice were put in the conditioning chamber (TSE Sys-
tems) for 3 min, after which a cue phase started with a series of
4.5 kHz tone pips (250 ms on and 750 ms off) for 28 s followed
by a one-time 2-s footshock (0.8mA). Animals were then left in
the box for another 30 s before being returned to their home
cage. 24 h later, contextual fear-conditioning memory was
measured; mice were placed back into the fear conditioning
box, and contextual freezing behavior was scored during 3min.
Freezing was defined as a lack of movement, except for heart-
beat and respiration, associated with a crouching posture and
was recorded every 10 s for 3 min (for a total of 18 sampling
intervals). The number of observations indicating freezing
obtained as a mean was expressed as a percentage of the total
number of observations.
Western Blot
The right cortex and hippocampus were dissected, and the
tissuewasweighed andhomogenized inRIPAbuffer containing
protease and phosphatase inhibitors. Brain homogenates were
then centrifuged at 20,000 g for 10 min at 4 °C, and superna-
tant was stored at80 °C until use. Protein lysates were quan-
tifiedwith bicinchoninic acid (BCA) assay (Pierce), separated in
SDS, 10% PAGE at 120 V for 2 h, and transferred to nitrocellu-
lose membranes. After incubating with primary antibodies,
membranes were blotted using IR-DYE 680 anti-mouse or IR-
DYE 800 anti-rabbit and detected with a LI-COR scanner
(Odyssey). Densitometry of bands was measured using ImageJ
software (21) and normalized to -actin or GAPDH.
Immunohistology
The left hemisphere of the mouse brain was post-fixed for 1
week in 4% paraformaldehyde/PBS buffer and coronally sec-
tioned using a vibratome (Leica 1000), at a thickness of 50 m
for the 3Tg-AD mice and 40 m for the CK-p25 mice. Four
brain slices were selected from each animal, at regular intervals
and spanning the anterior to posterior portions of the hip-
pocampus. For the PHF-1 and H2AX staining, slices were
treated with 50mMNH4Cl for 10min at RT, preincubated with
0.1% Triton X-100, 1% BSA, PBS for 1 h. Sections were double-
TABLE 1
Summary of drug efficacy in twomouse models


















CK-p25 i.c.v. 594; DMSO 50% 1 1 7/6 weeks 50%*** 62% Cell reversal*** 20%*
2 0.5 6/6 weeks 52%*** 39% Cell reversal * 80%***
i.c.v. 828; PEG 60% 3 1 3/6 weeks 51%*** 22% Cell Reversal 89%***
s.c./i.p. 594; PEGa 4 30/60b 4/3 weeks 61%*** 42% cell reversal** 78%***
s.c./i.p. 828; PEGc 5 30/60b 4/3 weeks 64%*** 48% cell reversal* 85%***
3Tg-AD i.p. 594; 40% PEG 6 60 6/1 week 99%** 91% DNA reversal ** 81%**
7 30 6/1 week 79%** 85% DNA reversal * 68%*
i.p. 828; 60% PEG 8 78 4/1 weeks 61%* 78% DNA reversal * 65%*
9 39 4/1 week 95%** 99% cell reversal ** 78%*
s.c. injection 594; 40% PEG 10 60 5/1 week 32% 60% cell reversal 40%
a Compound LDN-193594 was administered s.c. in 100% PEG and then administered i.p. in 40% PEG, 40% saline.
b 30 mg/kg/day s.c. infusion was for 2 weeks, followed by 60 mg/kg/day i.p. injection on the 3rd week.
c Compound LDN-193828 was administered s.c. in 100% PEG and then administered i.p. in 60% PEG, 40% saline.
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stained by incubation with PHF-1 and H2AX antibodies at
4 °C for 3 days; Alexa 488 anti-rabbit and Alexa 594 anti-mouse
were used as secondary fluorescent probes and incubated an
additional day in the presence of Hoechst 33342 (Calbiochem)
to fluorescently label cell nuclei. Slices were mounted in
microscopy glass slices using FluorSave mounting media (Cal-
biochem). The same procedure was applied for NeuN and
PHF-1 staining in CK-p25 mice except that NH4Cl treatment
was omitted. Staining for Fluoro-Jade (Millipore AG310) was
performed following the manufacturer’s recommendation
except on the first step of immersion in which slices were
immersed in 100% alcohol only. Confocal micrographs for hip-
pocampal CA1 neurons immunostained with PHF-1 and
H2AX or NeuN and PHF-1 were taken. Neurons visibly
stained by either PHF-1 and/or H2AX foci were observed,
manually classified using BioView software (22), and counts for
classified neurons obtained.
Sarkosyl Fractionation of Tau—Sarkosyl fractionation was
performed as described previously (23). Briefly, mouse hip-
pocampi from 3Tg-AD mice stored in RIPA buffer (50 mM
Tris-HCl, pH 7.4, 150mMNaCl, 1%Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS) with protease and phosphatase inhib-
itor were diluted with Sarkosyl buffer (50mMTris-HCl, pH 7.4,
150 mM NaCl, 1% Sarkosyl) to 1 ml, incubated head-over-head
at 4 °C for 30min, and pre-centrifuged at 20,000 rpm for 10min
at 4 °C. The supernatant was ultracentrifuged at 200,000 rpm at
4 °C for 2 h to pellet the Sarkosyl-insoluble fraction. After
removal of the supernatant, the pellet was dissolved by boil-
ing in Laemmli buffer (Bio-Rad) plus 20 mM DTT (Sigma) at
95 °C for 10 min, separated by SDS-PAGE, immunoblotted,
and subjected to sample preparation for mass spectrometric
(MS) analysis.
Statistical Analysis—Statistical evaluation was performed
using Student’s t test (for two treatment comparisons) or one-
way analysis of variance followed by Tukey’s post hoc analysis
(for multiple treatments comparisons). R project for statistical
computingwas used to compute statistical tests (version 2.13; R
development core team, 2011). Statistical difference was con-
sidered significant atp 0.05. For contextual fear conditioning,
statistical evaluation was performed using one-way analysis of
variance with Bonferroni’s multiple post hoc test.
Mass Spectrometry—For absolute quantification and deter-
mination of PHF-Tau and its diverse phosphorylation, we used
FLEXIQuant, a mass spectrometry approach that is based on
the addition of a full-length protein standard containing the
N-terminally tagged artificial tryptic FLEX-peptide into the
biological sample of interest (24). The FLEX-peptide absolute
quantity is predetermined from which the isotopically labeled
FLEX-TauH is quantified based on its ratio to the FLEX-peptide
and is used as an internal reference to quantify the endogenous
TauL based on its L/H ratio. As the 3Tg-AD mouse model
expresses the human 4R0N isoform of Tau, we prepared the
isotopically labeled FLEX-TauH by subcloning the longer Tau
isoform human 4R1N Tau into the FLEX-peptide containing
expression vector. After wheat germ expression and His tag
purification, isotopically labeled [13C6]Lys and [13C6]Arg Tau
standards (FLEX-TauH) were in-gel digested by trypsin.
Protein lysates from one-quarter of each hippocampus were
Sarkosyl-extracted to enrich for PHF-Tau. The Sarkosyl-insol-
uble pellet was separated via SDS-PAGE and probed with
PHF-1 antibody to confirm enrichment of PHF-Tau at 65 kDa.
A similar gel prepared in parallel was Coomassie-stained, and
gel segments corresponding to a molecular mass of 65 kDa
were excised from both vehicle and LDN-193594-treated
samples. These gel segments were subjected to in-gel trypsin
digestion. As Western blotting indicated large differences in
PHF-Tau levels in these samples, an appropriate amount of
FLEX-TauH was added into the sample to ensure an approxi-
mate 1:1 light to heavy (L/H) ratio of Tau peptides within the
subsequent MS analysis. In the MS analysis, the nonlabeled
version of the FLEX-peptide (TENLYFQGDISR) was added to
the L/H peptide mix at a concentration of 10 fmol/l (three
technical repeats). To produce a heavily labeled FLEX-Tau pro-
tein standard (FLEX-TauH)with anN-terminalHis6 tag and the
FLEX-peptide (TENLYFQGDISR), full-length human 4R1N
Tau (gi:294862254) was subcloned into the previously gener-
ated pEU-E01-TEV-N1-AQUA vector (24). After the WGE
translation reaction, FLEX-TauH was batch-purified using
nickel-Sepharose beads (nickel-Sepharose high performance
resin, GE Healthcare).
RESULTS
Diaminothiazoles, a Novel CDK5 Inhibitor Series—We
described previously a series of diaminothiazole compounds
that inhibit CDK5 within the nanomolar range. LDN-193594
(compound 26 in Ref. 19) shows an in vitro IC50 of 30 nM and
EC50 of 5.5Mwhen evaluated in rat primary neuronal cultures.
To test the biological stability of LDN-193594, we incubated it
with microsomes for 1 h. Using LC/MS/MS, we estimated that
its half-life is30 min. This relatively short half-life suggested
that LDN-193594might be a substrate of CYP450 oxidation. To
track down the putative oxidation site without purifying all the
metabolites, the fragmentation pattern of the product gener-
ated by mass spectrometry was carefully examined. One of the
major metabolites in the fragmentation pattern clearly sug-
gested that an oxygen atom had been added to the pyridine,
because an increase of 16 Da in the mass of the fragment was
observed (data not shown). Given these data, a molecule with
trifluoromethyl to block the 6-position of the 3-pyridine was
synthesized (LDN-212853); this molecule exhibited an
extended half-life (Fig. 1). Additional derivatives of this series
were synthesized by introducing hydrophilic groups, such as
piperidine, morpholine, and piperazine, at the 6-position of the
3-pyridine. The synthesized compounds were analyzed for
their ability to inhibit CDK5 via an in vitro kinase assay and in
primary neuronal cultures. As shown in Fig. 1, LDN-193665 has
the higher potency in primary cultures and LDN-193594 in
vitro. The inhibition potency decreased, as reflected by EC50
and IC50, whereas microsome stability improved, i.e. LDN-
213828 has the longest half-life in microsomes, about three
times that of LDN-193594. All compounds selected for further
testing have an LD50 greater than 100 M, about 8-fold greater
than the EC50 of LDN-213828.
To establish a drug delivery protocol that is suitable for effi-
cacy testing in animals, we studied possible formulations of this
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series of compounds. The excipient PEG 400 greatly improved
the solubility of all compounds (Fig. 1). Solubility in 40% PEG
400 dropped dramatically for LDN-193665 and -213828. LDN-
193594 remained soluble at a concentration of 12mg/ml. LDN-
213842 and -213843 have better aqueous solubility (100 and
1000 M, respectively) than LDN-213828, consistent with the
calculated LogP values, although their PEG 400 solubility was
lower than that of LDN-213828.
Pharmacokinetics of the diaminothiazoles was studied in the
3Tg-AD mice. LDN-193594 was administered i.p., and its
concentration was measured in plasma and brain samples at
different times after injection (Fig. 2A). Data were fitted to a
one-compartment model (see “Experimental Procedures”).
The parameters obtained are indicated in Fig. 2A, inset table.
LDN-193594 is rapidly absorbed and permeates the blood brain
barrier, reaching Cmax at 10 min, with 161 M observed in
plasma and 69M in brain. The average plasma brain ratio calcu-
lated is 0.34 0.04. This concentration is2000-fold the calcu-
lated IC50 and 12-fold the EC50 observed. LDN-193594 clearance
appears faster in the brain than in the plasma, with a calculated
half-life of 0.71 h in the brain and 1.2 h in plasma.
We tested CDK5 activity in vivo after injection with LDN-
193594 using the immunoprecipitation method previously
described (16, 25). Young adult mice (1 month old CD1) were
i.p.-injected with 120 mg/kg LDN-193594. After 15 min, mice
were euthanized with CO2, the brains removed, and cortex
lysates homogenized and immunoprecipitated with CDK5
antibody or isotype immediately (Fig. 2B). [-32P]ATP phos-
photransfer to H1 peptide was tested by in vitro radioactivity
kinase assay (Fig. 2,C andD). Data are reported as percentage of
32P transfer to H1 in treated mice compared with vehicle mice.
CDK5 activity in the mice treated with LDN-193594 was
reduced 37% (Fig. 2E) (n 4, p 0.064).
LDN-213828 and LDN-213843 were i.v. administered. LDN-
213828 permeates the blood brain barrier with an average brain
plasma ratio of 0.25  0.06. The Cmax in the brain was 31 M,
detected 5 min after injection. LDN-213843 was undetectable in
brain lysates. This result was partially predictable by theoretical
analysis; as a general rule, compounds with a polar surface area of
90 Å2 and a number of hydrogen bond donors of3 (26) may
havebetter bloodbrainbarrier permeability; thepolar surface area
of LDN-213843 is 96 Å, and it has four hydrogen bond donors.
We concluded that LDN-193594, -193665, and -213828were
leads for assessing the effects of this diaminothiazole series in
vivo. Because of structural similarities between LDN-193594
and -193665, we decided to assess LDN-193594, the most
potent inhibitor in vitro, and LDN-213828, the most biostable
inhibitor of our series. We assessed the toxicity of these in vivo.
LDN-193594 was administered i.p. at 120, 60, and 30 mg/kg/
day for 7 consecutive days. Two of the three mice treated with
the maximum dose died after 3 days of treatment. The third
mouse presented major body weight loss by day 5, surpassing
the established end point of losing more than 15% of the origi-
nal weight. Sixmice treatedwith all other doses assayed, vehicle
(40% PEG 400) or PBS, suffered no major weight loss, with a
maximum weight loss averaging 6% (Fig. 2F). In addition, mice
displayed no symptoms of pain or distress; they groomed and
ate normally and appeared active. Four mice per group treated
with 78 or 39 mg/kg/day LDN-213828 or vehicle (60% PEG
400), by similarmethodology, displayed no evident signs of tox-
icity and experienced a maximum weight loss averaging 8%.
Treatment with Diaminothiazole Kinase Inhibitors Exerts
Neuroprotective Effects in Vivo—Compounds LDN-193594 and
-213828 were studied in two mouse models via various admin-
istration methods as summarized in Table 1. Neuronal protec-
tive effects were immunohistochemically evaluated by visualiz-
FIGURE 1. Structure and chemical and biological properties of diaminothiazole. a, IC50 for CDK5 was determined on 40 M histone H1-derived peptide
PKTPKKAKKL (H1P), 60M ATP, and 6.6 nM Cdk5/p25 enzyme; IC50 for GSK3was determined on 40M glycogen synthase peptide-2 (GSP-2), 60M ATP, and
55 nM GSK3. b, CDK5 kinase activity in primary neuronal culture was evaluated using neuronal primary culture prepared from brain hippocampus of E18 rat
fetuses. c, LD50 was measured after 24 h of incubation as described previously (18) using the CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega). d,mouse microsome stability of the compounds was decided at 10 M using pooled male mouse liver microsomes (BD Biosciences, B6C3F1). The
reactionmixture was analyzed using HPLC-UVmethod. e, solubility was accessed by turbidity. f, values for cLogP and polar surface area were calculated using
molinspiration. g, 60% PEG 400 was used.
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ing NFT formation with the PHF-1 antibody, and neuronal
survival or DNA damage was evaluated using antibodies to
NeuNorH2AX.Quantification of the signal was performed in
the CA1 area of hippocampus. Tau phosphorylation was
assessed by Western blotting with the PHF-1 antibody.
In vivo efficacy of the diaminothiazole inhibitors in PHF-1
neurons was assayed in a CK-p25 mouse model 6 weeks after
induction. In thesemice, the induction of p25-eGFP expression
in the brain causes CDK5 activation. The neurotoxicity associ-
ated with p25 overexpression is progressive. Two weeks after
p25-eGFP induction, cell death and learning and memory
impairment were not yet present, and virtually all neurons in
the pyramidal layer expressed the transgene that fills the cyto-
plasm, and cells present an extensive dendritic arborization
similar to the morphology of healthy control CA1 pyramidal
neurons (Fig. 3A). After 6 weeks, p25-eGFP is mostly limited to
FIGURE 2. Pharmacokinetics, ex vivo CDK5 inhibition, and toxicity of diaminothiazole kinase inhibitors. A, concentration of LDN-193594 in plasma
(continuous line) and brain (dashed line) was measured using HPLC/UV. Data are shown as concentration (M) measured in mean  S.E. Pharmacokinetics
parameters obtained are reported in the inset. Average plasma brain ratio of 0.34 0.04was calculated from the brain and plasma concentration at each time
point.AUC, areaunder the concentration-time curve;Vd, volumeof distribution; T1⁄2, eliminationhalf-life derived from thequotient of 0.693 and the elimination
rate constant; Cmax, maximum concentration measured; Cl, clearance, derived from the equation Cl Vd0.693/T1⁄2. B–E, ex vivo kinase assay confirmed that
LDN-193594 reducesCDK5 kinase activity.B,CDK5was immunoprecipitated from1-month-oldCD1mice 15min after i.p. injectionof thedrug candidate or the
vehicle. CDK5 activitywas immediatelymeasured by in vitro radioactivity kinase assay. RepresentativeWestern blot image for CDK5 immunoprecipitationwas
probed with rabbit anti-CDK5 antibody. C, radioactivity of the phosphorylated H1 peptide as the CDK5 phosphorylation product was detected on p81 phospho-
cellulose paper at reaction times of 10, 30, and 60min. The reactionwith the recombinant CDK5/p25was used as a positive control, and in the negative control the
enzyme was replaced with the protein fraction using IgG immunoprecipitation. D, representative data show the linear rate of product formation, presented by
concentrationof thephosphorylatedH1peptide (M)over time (min). E, bar graphdemonstrates that the reaction rate frommice that hadbeen treatedwith a single
injection of 120mg/kg LDN-193594 is 37% reduced comparedwith themice treatedwith vehicle alone. Data are presented asmean S.E. n 4. p 0.064. F, daily
i.p. administration of diaminothiazoles for 1week did not causemajorweight loss. Average bodyweight loss at day 7 is shown asmean S.E.Mice treatedwith 120
mg/kg/daywere removed from the assay at or before day 5 due to 15%bodyweight loss. Mice treatedwith all other doses survived the experiment.
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a few remaining pyramidal cell bodies and does not extend into
the dendritic region, most likely reflecting cellular atrophy
associatedwith the neurotoxicity (Fig. 3B). Extensive neurotox-
icity occurring in the CA1 region of the hippocampus is associ-
ated with deficits in learning and memory (9, 20). Mice that
were treated with LDN-193594 i.c.v. for 6 weeks after p25
induction showed a cytoplasmic and dendritic pattern of p25-
eGFP distribution similar to that at an earlier time after induc-
tion, including a higher number of cells expressing the trans-
gene, implicating a reduction in the cellular atrophy associated
with p25 overexpression.
NeuN staining was used to assess the extent of neuronal loss
in these mice. The average number of CA1 neurons was
reduced from 2100  20.00 NeuN cells/mm2 in control CK
mice (representative image shown in Fig. 3A) to 1200 
61.24 in CK-p25 mice, 6 weeks after p25 induction (Fig. 3A).
NeuN density recovered to 1692  109.6 for mice that
received LDN-193594 i.c.v. and to 1764  100.49 following
s.c./i.p. treatment. This improvement corresponds to 40%
recovery in both cases (Fig. 3, B and C). A neuroprotective
effect was also observed in mice treated with LDN-213828
i.c.v. but did not achieve statistical significance; however,
FIGURE3.Neuroprotective effect indiaminothiazole-treatedCK-p25mice.Micewere sacrificedby intracardiac perfusion. Brainswere collected, post-fixed
overnight, and sliced at a 40-mwidth. Brain slices were stainedwith anti-NeuN or PHF-1 followed by anti-mouse IgG1-Alexa 594 or stainedwith Fluoro-Jade.
Nucleiwere counter-stainedusingDAPI. High resolution40 confocal imagesdisplayingCA1pyramidal layer of thehippocampal regionat Bregma1.90mm
were acquired (n3), bar, 40m. A, representative images display NeuN and PHF-1 immunoreactivity in the uninduced CK-p25mice. B, increased number of
NeuN cells are observed in diaminothiazole-treated CK-p25. Mice were i.c.v.-treated for 6 weeks with LDN-193594 at 1 mg/kg/day or vehicle (50% DMSO)
using subcutaneously implanted Alzet pumps (experiment 1). C, histogram summarizes the neuroprotective effect observed after diaminothiazole treatment
in experiments 1–5 as compared with vehicle (v). NeuN cells were counted using ImageJ cell counter plugin, and the number of NeuN cells per CA1 region
was calculated (mean S.E.). D, representative images show a decreased number of Fluoro-Jade cells are observed in LDN-193594-treated CK-p25mice via
i.c.v. at the dose of 0.5 or 1 mg/kg or via s.c./i.p. at the dose of 30/60 mg/kg (experiments 1, 2, and 4). E, histogram summarizes the neuroprotective effect
observed based on the Fluoro-Jade staining. F, perinuclear mislocalized PHF-1 immunoreactivity is reduced by diaminothiazole treatment (experiment 1). G,
histogram summarizes the average fluorescence intensity of PHF-1 in experiments 1–5, quantified in two regions of the CA1 pyramidal layer, a perinuclear and
a neuritic region, as indicated by yellow squares presented in F. The fluorescence ratio of perinuclear to neuritic region was calculated, and values were
normalized to that of vehicle.Normalizeddata arepresentedasmeanS.E.Where applicable, statistical significance is indicatedwithn.s.,not significant; *,p
0.05; **, p 0.01; ***, p 0.001.
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systemic delivery of this compound gave a 48% recovery (p
0.05).
Fluoro-Jade stain is a fluorochrome derived from fluorescein
and is commonly used to stain degenerating neurons. This
methodwas validated inmodels of cell death such as kainic acid
(27), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (28), or
multivalent metals (29) in vivo and showed similar results as
quantification of cell death using conventional hematoxylin
and eosin, Nissl, or de Olmos’ cupric-staining methodologies
(30). Typically, Fluoro-Jade-positive neurons also present a
condensation of the chromatin, a disruption of the plasma
membrane, and nuclearmembrane integrity. The neuroprotec-
tive effect of LDN-193594 was confirmed as the number of
degenerating neurons was reduced 60% in the treatment with
LDN-193594 at 1 mg/kg dose, 50% at 0.5 mg/kg dose by i.c.v.,
and 50% at 30/60 mg/kg dose by s.c./i.p. (Fig. 3, D and E).
Neuronal toxicity associated with p25-eGFP expression was
supported by the observation of intense perinuclear PHF-1 sig-
nal in CA1 pyramidal neurons in untreated mice following 6
weeks of p25 induction (Fig. 3F), and it was significantly
reduced in mice treated i.c.v. with LDN-193594. The treated
PHF-1 staining pattern was similar to that of uninduced
CK-p25 mice (Fig. 3A). To quantify those changes, we mea-
sured the fluorescence intensity of PHF-1 and calculated the
signal ratio between background and the perinuclear area of
CA1 (indicated by the yellow squares in Fig. 3F), and we nor-
malized it to the ratio in the vehicle (DMSO)-treated CK-p25
mice. The ratio was found to increase after p25 induction
reflecting the accumulation of the PHF-1 signal around the cell
body, whereas treatment with LDN-193594 by either i.c.v. or
s.c./i.p. administration significantly reduced this ratio and the
perinuclear aggregation of PHF-1. LDN-213828 also proved
effective when administered s.c/i.p. for the last 3 weeks, in a
similar manner (Fig. 3G).
3Tg-ADmice (23months old) were also treatedwith LDN-
193594 by daily i.p. administration for 1 week. Immunohisto-
logical presence of PHF-1 neurons in the hippocampi was
evaluated. This ADmousemodel harbors mutations that cause
the presence of both -amyloid plaques and Tau NFTs in an
age-related manner. Previously, transmission electron micros-
copy detected straight Tau filaments, immunoreactive to the
phosphorylatedTau antibodies, Alz50 andAT8 at 23months of
age, but not at 2 or 9 months (31). By analyzing a series of
coronal slices spanning most of the hippocampus rostrocau-
dally, we observed PHF-1 cells mainly in the CA1 area, with
occasional detection in CA2 and dentate gyrus. These PHF-1
neurons appear to predominate in the dorsocaudal CA1, with a
peak of detection aroundBregma1.5-mmslices.Mice treated
i.p. with vehicle alone (40% PEG 400) presented an extensive
amount of PHF-1 neurons in the CA1 pyramidal layer in the
posterior hippocampus; mice treated i.p. with LDN-193594 (30
and 60 mg/kg/day) show few detectable PHF-1 neurons (Fig.
4A). A similar reduction occurred in mice that were treated
with LDN-213828 compared with vehicle (60% PEG 400) in
PHF-1 neurons (Fig. 4A).
Co-staining with Hoechst 33342 allowed us to calculate the
density of nuclei in this area as 2000 nuclei/mm2. The num-
ber of nuclei quantified in mice with different treatments did
not change (Fig. 4B). The number of PHF-1 CA1 neurons per
100 nuclei was quantified to 11.6 0.25 in the vehicle-treated
mice. LDN-193594 i.p. treatment significantly reduced this
number to 0.12 0.02 (60 mg/kg/day). PHF-1 neurons were
undetectable in mice treated intraperitoneally with 39 mg/kg/
day LDN-213828 and 4.5  0.60% PHF-1 with a dose of 78
mg/kg/day (Fig. 4C). However, when LDN-193594 was admin-
istered via s.c. injection, the reduction in the number of PHF-1
neurons in the hippocampus was not significant (Table 1).
To assess the vulnerability of the neurons in the 3Tg-AD
mouse model, we aimed to evaluate the extent of DNA double
strand breakage using a phospho-H2AXantibody (32). Immu-
nohistological co-labeling of 23-month-old 3Tg-AD mice
with PHF-1 and H2AX showed detectable H2AX foci pres-
ent in CA1 neurons that also labeled with PHF-1. Although
3Tg-AD mice treated with vehicle (40–60% PEG 400) pre-
sented a large amount of PHF-1 cells as well as H2AX cells
(Fig. 4D), mice treated intraperitoneally with either LDN-
193594 or LDN-213828 for a week showed a major reduction in
cells with H2AX foci (Fig. 4E). Quantification of the number of
H2AX neurons in the CA1 region showed that 8.26  0.70
H2AX cells per 100 nuclei were found in the CA1 region of the
hippocampus.Oneweekof i.p. treatmentwithLDN-193594 led to
a 10-fold reduction (60mg/kg/day) (p 0.01), and treatmentwith
LDN-213828 led to a 4-fold reduction (78 mg/kg/day) (p 0.05).
H2AX and PHF-1 cells were both undetectable when mice
were treated with LDN-213828 at 39mg/kg/day.
High resolution confocal micrographs with Z-stack three-
dimensional reconstruction of double-labeled PHF-1/H2AX
slices showed that H2AX is present in the perinuclear cyto-
plasm of PHF-1 cells in the hippocampus, instead of the
expected nuclear compartment. The probability that a given
H2AX cell was also stained with PHF-1 was equal to 0.97
2.1. Therefore,mostH2AX cells were also PHF-1 cells. The
probability of co-localization did not change after treatment
with diaminothiazoles which reduced both markers. This find-
ing strongly suggests a link between NFT-bearing neurons and
H2AXDNA damage and is consistent with evidence fromAD
brains that show double-stranded breaks are more prevalent
than in normal human aging brains (33). To our knowledge,
abnormal cytosolic accumulation of H2AX has not been pre-
viously described in the 3Tg-AD model.
Diaminothiazole Kinase Inhibitors Reduce Tau Phosphor-
ylation—To investigate the effect of the treatment on Tau
phosphorylation in these mouse models, PHF-1 antibody was
used. This antibody recognizes Tau phosphorylated at Ser-396
and Ser-404 (34). The PHF-1 immunoreactive signal, virtually
undetectable in CK control mice (data not shown), has a very
strong signal in the CK-p25mice. Treatment of thesemice with
LDN-193594 and -213828 via i.c.v. for 6 weeks reduced the
intensity of the PHF-1 immunoreactive band to nearly nonde-
tectable levels (Fig. 5, A and B). A similar reduction was
observed in s.c./i.p.-administered LDN-193594 and LDN-
213828. To determinewhether the observed reduction ofNFTs
(Fig. 4A) found in treated 3Tg-AD mice correlated with the
phosphorylation of Tau, we analyzed protein lysates of brains
from 3Tg-ADmice byWestern blotting. In this model, a Tau
band of65 kDawas enriched by fractionatingTauwith Sarko-
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FIGURE 4.Diaminothiazole treatment reduces PHF-1 and H2AX CA1 neurons in 3Tg-ADmousemodel. A, PHF-1 immunoreactive cells indicative
of NFTs in 3Tg-ADmice were cleared by administration of diaminothiazoles. Aged 3Tg-ADmice (23months) were administered i.p. with vehicle (40–60%
PEG 400) or either kinase inhibitor LDN-193594 (30 and 60 mg/kg/day) or LDN-213828 (39 and 78 mg/kg/day) for 1 week (experiments 6–9). Mice were
sacrificed by intracardiac perfusion, and brains were post-fixed in 4% paraformaldehyde for an additional week. Coronal brain slices 50 m thick were
immunostained with mouse PHF-1 antibody and detected with anti-mouse IgG1 Alexa 594. Hoechst 33342 was used to stain cell nuclei. Z-stack confocal
micrographs with 15 planes 1 m each, spanning the CA1 pyramidal layer in at least four brain sections per mouse, were obtained at40 magnification and
high resolution. Representative images are shown, displayingmaximum Z-stack projections on Bregma2.18mm for mice with different treatments. Bar, 50
m. B,CA1 pyramidal layer cell body density remains constant in vehicle (v) and diaminothiazole-treated 3Tg-ADmice. Nuclei specifically located in the CA1
pyramidal layerwere countedusing ImageJ cells counterplugin in at least four sectionspermouse. CA1areawasmeasured fromthe images, andnuclei density
was calculated as nuclei/mm2. Data are reported asmean S.E. C, PHF-1 immunoreactive cells were counted per image as indicated above, and a number of
PHF-1 immunoreactive neurons in CA1 pyramidal layer for every 100 nuclei were calculated. Data are presented asmean S.E.D, reduction of Ser(P) histone
H2AX cells associated with PHF-1 cells in CA1 pyramidal layer of treated 3Tg-AD mice. The same tissue as indicated in A was stained with H2AX.
RepresentativemaximumZ-stackprojectionsonBregma1.00mmare shown;bar,50m. E, cells displaying foci ofH2AXand thenuclei in theCA1pyramidal
region were counted, and CA1 area was measured. Percentage of H2AX cells per nuclei was calculated and presented as mean S.E. Where applicable,
statistical significance is indicated: *, p 0.05, and **, p 0.01. ND stands for not detected.
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syl and is likely to be comparable with theA68-hyperphosphor-
ylated Tau band from human AD patients (35). Similar bands
have been reported in JNPL3 mice containing the same human
Tau mutation (36). After treatment with the vehicle or LDN-
193594, the cortex and hippocampal lysates were analyzed (Fig.
5, C and D), and the 65-kDa Tau band was mainly observed in
the hippocampus and strongly reduced in a dose-dependent
manner by LDN-193594 treatment (Fig. 5C). The intensity of
the 65-kDa band appeared strongly correlated with the num-
bers of PHF-1 neurons (Fig. 4A), R2  0.69 (Fig. 5E). Other
immunoreactive Tau bands with a lower apparent molecular
weight did not show this correlation (Fig. 5F). The total Tau
level, immunoblotted by antibody Tau-5, was not changed with
LDN-193594 treatments compared with vehicle control (data
not shown). We verified the reduction in the 65-kDa PHF-1
Tau band with LDN-193594 administered intraperitoneally at
30 and 60 mg/kg/day and with LDN-213828 administered
intraperitoneally at 39 and 78 mg/kg/day (Fig. 5D).
Quantitative MS Confirms That Diaminothiazole Decreases
Sarkosyl-insoluble PHF-Tau Levels as Well as Its Phosphoryla-
tion State—Protein samples were prepared from 23-month-old
3Tg-AD mice treated with vehicle only (40% PEG 400) or
LDN-193594 (60 mg/kg/day). Protein lysates from hippocampi
were Sarkosyl-extracted to enrich for PHF-Tau. The Sarkosyl-
insoluble pellet was separated via SDS-PAGE and probed with
PHF-1 antibody to confirm enrichment of the PHF-Tau at 65
kDa. As described above, the PHF-Tauwas strongly enriched in
the vehicle-treated mice hippocampi. However, this band was
not detected in the Sarkosyl fraction of the LDN-193594-
treated mice (Fig. 6A).
FIGURE 5. Tauphosphorylation is reducedby kinase inhibitor diaminothiazole series in vivo. A and B, phosphorylated Tau at 55 kDa detected by PHF-1 is
reduced by diaminothiazole treatment in CK-p25 mice. A, representative images of the reduction in PHF-1 signal following treatment with LDN-193594
comparedwith the vehicle-treatedmice (experiments 1, 2, and 4).Western blots of CK-p25mice did not reveal a PHF-1 65-kDaband. B, ratio of PHF-1 to-actin
densitometry was calculated and normalized to vehicle (v). Normalized values are reported as mean  S.E. n 3. C and D, phosphorylated Tau at 65 kDa
detected by PHF-1 was specifically reduced by diaminothiazole treatment in 3Tg-AD mice. C, representative images showing reduction of PHF-1 signal
following treatment with LDN-193594 compared with the vehicle-treated mice. Cortex (left) and hippocampus (right) are shown. The arrow indicates the
65-kDa phospho-Tau band reduced with treatment. D, ratio of PHF-1 to -actin densitometry was calculated for the 65-kDa band in experiments 6–9, and
normalized to vehicle. Normalized values are reported asmean S.E. n4. E and F, correlation of PHF-1 cell numberswith densitometry of 65 kDa (E) and 55
kDa (F) PHF-1 Tau bands by Western blotting. Statistical significance is indicated: *, p 0.05, and **, p 0.01.
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The absolute amount of Sarkosyl-insoluble Tau in the
peptide mix was determined by analyzing L/H ratios of the
quantified FLEX-TauH peptides to corresponding endoge-
nous peptides, 243LQTAPVPMPDLK254, 282LDLSNVQSK290,
and 354IGSLDNITHVPGGGNK369, which were unchanged
between vehicle and LDN-193594-treated samples and were
detected with high signal intensities in all technical and biological
replicates. In two independent experiments, mice treated with
LDN-193594 (3 and 0.4 ng/hippocampus) showed a reduction to
1.5% in total Sarkosyl-insoluble PHF-Tau compared with vehi-
cle-treatedmice (135 and 48 ng/hippocampus (Fig. 6B).
Current models of the Tau phosphorylation pattern associ-
atedwithADpoint to twoCDK5 phosphorylation sites, namely
Ser-235 and Ser-404 (34). The extent of CDK5 activity on Tau
could be measured by monitoring these sites. Tryptic peptides
containing these sites were analyzed to determine their suit-
FIGURE 6. Mass spectrometry of hippocampal protein lysate from 3Tg-AD mice treated with either vehicle or LDN 193594. A, hippocampi from
23-month-old 3Tg-AD mice with either LDN-193594 (60 mg/kg/day) or vehicle alone by i.p. delivery were used to prepare a Sarkosyl-insoluble protein
fraction. This Sarkosyl-insoluble fractionwas separatedby SDS-PAGE andprobedwith PHF-1 antibody. The immunoblot shows a clear enrichment for a 65-kDa
phospho-Tauband in theSarkosyl-insoluble fraction in thevehicle-only treatedmouse,whereas theLDN-194594-treatedmousedoesnot showa signal for this
65-kDa phospho-Tau protein. B, corresponding 65-kDa areas were excised from a Coomassie-stained gel and trypsinized from the LDN-193594 and vehicle-
treated samples and quantified using our FLEX-TauH method using a scheduled multiple reaction monitoring assay. Absolute protein amounts were deter-
mined for the total Sarkosyl-insoluble PHF-Tau. Two independent biological replicateswith three technical repeats each are shown. In both biological repeats,
the amount of Tau in the PHF-1-positive fractionwas significantly decreased in the LDN-193594-treated comparedwith vehicle condition. Data are presented
as mean  S.E. Statistical significance is indicated: **, p  0.01. C, for this analysis, three representative peptides present in similar ratios and unchanged
betweenvehicle- andLDN-193594-treated sampleswereused tonormalize comparisonsbetween samples. Light toheavy ratiosofnormalized intensity values
for these three peptides as well as the tryptic peptide 396SPVVSGDTSPR406 are shown (n  2). Normalized data are presented as mean  S.E. D, using the
FLEXIQuant approach, the extent of modification of the peptide 396SPVVSGDTSPR406 was calculated for vehicle-treated (40% PEG 400) and LDN-193594-
treated 3Tg-ADmice. The vehicle-treated sample exhibited 81%modification of the SPVVSGDTSPR peptide, whereas the LDN-193594-treated sample was
32%. Thus, LDN-193594-treated samples displayed a significantly decreased amount of PHF-1-positive insoluble Tau and a decreased extent of insoluble Tau
modification. E, Sarkosyl-insoluble Tau of 3Tg-ADmice samples treated with vehicle only was subjected to LC/MS/MS analysis on a Q Exactive tandemmass
spectrometer. The MS/MS spectrum of the phosphopeptide 396SPVVSGDTSpPR
406 is depicted. The y-series fragments support a mono-phosphorylation at
either Thr-403 or Ser-404 (Ser-404 depicted exemplarily).
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ability for quantitative measurements. The Ser-235 site is
located on peptide 235SPSSAK240 in a tryptic digest. This pep-
tide was not detectable even with multiple reaction monitor-
ing methods, and therefore quantification of this modifica-
tion site was not possible. We therefore focused on the
tryptic peptide containing the phosphorylation site at Ser-
404 (396SPVVSGDTpSPR406), which coincides with a recogni-
tion site of the PHF-1 antibody. Peptide intensities were nor-
malized for different amounts of Tau in each sample using the
above-mentioned unmodified peptides. In Sarkosyl-insoluble
Tau samples of vehicle-treated 3Tg-AD mice, 19% of this
peptide is unmodified and 81% is modified, whereas after treat-
ment with LDN-193594, 68% is unmodified and 32% modified
(Fig. 6C). Thus, the modification of this tryptic peptide in
Sarkosyl-insoluble PHF-Tau of 3Tg-AD mice decreased by
60% upon treatment with LDN-193594.
The FLEXIQuant approach provides information about the
extent ofmodifications based on the reduction of the respective
unmodified peptides; however, it does not provide information
about the type of modification and the amino acid-specific
localization of themodification. As immunoreactivity with PHF-1
antibody (34) suggests the occurrence of Tau phosphorylation on
Ser-396 and Ser-404 in these samples, we performed a phosphor-
ylation analysis by LC/MS/MS of Sarkosyl-insoluble Tau from
3Tg-ADmouse hippocampi treated with vehicle only, targeting
all possible phosphorylation sites using an inclusion list of m/z
values corresponding to singly and doubly phosphorylated tryptic
peptides. In these samples, we found spectral evidence for a sin-
gle phosphorylation on the 396SPVVSGDTSPR406 peptide at
either Thr-403 or Ser-404 (Fig. 6D). Interestingly, diphosphor-
ylation of the Tau peptide that would be predicted to occur at
Ser-396 and Ser-404 was not identified. The concentration of
this species may have been below the detection limit of the
instrument, due to the low amount of Sarkosyl-insoluble Tau in
the samples. However, it is likely that the diphosphorylated
form of 396SPVVSGDTSPR406 was less abundant than the
monophosphorylated forms.
Diaminothiazole Kinase Inhibitor Restores the Learning and
Memory Abilities—Finally, we investigated the effect of the
LDN-193594 treatment on the learning andmemory deficits in
the CK-p25 mice. In this model, the neuronal loss following 6
weeks of p25 overexpression is associated with a deficit in hip-
pocampus-dependent memory in the fear-conditioning task
(20). To test the effect of the LDN-193594 treatment on this
learning deficit, CK-p25 mice or CK-only control littermates
were separated into two groups and treated either with LDN-
193594 or vehicle. Alzet pumps delivered a 2-week subcutane-
ous infusion during weeks 4 and 5 of p25 induction, followed by
i.p. injection during the 6th week. At that time, the hippocam-
pus-dependent cognitive ability of those mice was tested in
contextual fear conditioning, with a training phase followed by
a testing phase 24 h later. Freezing results from the CK control
mice receiving either vehicle or LDN-193594 showed similar
freezing behaviors in this task with no statistical differences
between the two groups. However, CK-p25 mice treated with
vehicle showed a 48% decrease in their learning abilities in con-
textual fear conditioning compared with control CKmice. This
deficit in the LDN-193594-treated mice was rescued to the lev-
els of control CKmice following LDN-193594 treatment as the
learning abilities of those mice were no longer statistically sig-
nificant from the control mice (Fig. 7, A and B). This result
showed that the positive effect of the treatment on both neuro-
nal survival and Tau phosphorylation also translated into a res-
cue of the learning abilities of the CK-p25 mice in this learning
and memory task.
DISCUSSION
A small molecule in the chemical class of diaminothiazoles
can inhibit Tau phosphorylation and exert neuroprotective
effects in two distinct, well knownADmousemodels as follows:
3Tg-AD (17) mice that contain both A amyloid and neuro-
fibrillary tangles, andCK-p25 (9)micewith up-regulatedCDK5
activity and neurofibrillary tangles. The in vivo neuroprotective
effect is mediated in part by inhibition of Tau phosphorylation
at sites identified by mass spectrometry of the insoluble Tau in
the 3Tg-AD model. Furthermore, in the CK-p25 model,
treatment also resulted in a recovery of memory in a fear con-
ditioning assay. The lead compound in this study, LDN-193594,
FIGURE7.LDN-193594 treatment recovers the learningandmemoryabil-
ities of CK-p25 mice examined in contextual fear conditioning. A,
response to the external stimulus (ES) during phases one and two was mea-
sured and showed no difference between the four experimental groups. B,
percentage freezing in CK-p25-inducedmice are increased from 25% in vehi-
cle-treatedmice to 60%with LDN-193594 treatment, a level comparablewith
learning and memory abilities of the control CK vehicle-treated mice. Statis-
tical significance is indicated: **, p 0.01; ***, p 0.001.
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emerged fromHTS and medicinal chemistry as a potent inhib-
itor of both CDK5/p25 and GSK3 (19). LDN-193594 has
favorable chemical properties with a cLogP of 3.1, a polar sur-
face area of 83 Å2, and aqueous solubility of20 M. It passes
the blood brain barrier and was observed at a concentration of
161M in plasma and 69M in the brainwith an average plasma
brain ratio of 0.34  0.04. Formulation with PEG 400 greatly
improved the solubility of the diaminothiazole compounds
(Fig. 1). LDN-193594 can be solubilized in 40% DMSO, 22%
2-hydroxypropyl--cyclodextrin in 0.9% saline up to 50mg/ml,
but 2-hydroxypropyl--cyclodextrin can alter Tau and A
aggregation (37). With 40% PEG in water, 12 mg/ml solubility
was reached, a concentration that allowed for a 120mg/kg dose
for i.p. injection in adult mice, which leads to inhibition of
CDK5 kinase activity in mice observed in ex vivo kinase assay.
The compound showed no sign of toxicity within our therapeu-
tic dose range. Blocking the 6-position of the 3-pyridine (LDN-
212853 and LDN-213828) resulted in an extension of the half-
life (Fig. 1). However, a metabolite of LDN-193594 with a
molecular weight of 490, which represents a 176 mass increase
above the parentmolecule was present in plasma, but not in the
brain, indicating the possibility of a glucuronide reaction in
plasma that modifies the compound in vivo through othermet-
abolic pathways.
The drug effect on Tau pathology in 3Tg-AD mice was
observed by both Western blot and immunohistochemistry
with PHF-1 antibody. PHF-1 antibody selectively recognizes
phosphorylated Ser-396/Ser-404 of Tau (23, 34) and labels
NFTs in tissue (31). Western blots from 3Tg-AD brains
showed that a 65-kDa PHF-1 immunoreactive band correlated
with the number of hippocampal NFTs. The phosphorylation
status of the Tau band is based on the observation that after
treatment by phosphatase the band co-migratedwith nonphos-
phorylated recombinant Tau (39). Quantitative mass spec-
trometry analysis confirmed this observation by showing that
the amount of PHF-1-positive Tau in the LDN-193594-treated
sampleswas reduced to1.5% of that observed in the vehicle-
treated control samples. Furthermore, the residual 2% of Tau
found in the Sarkosyl-insoluble fraction, which migrated at
65 kDa, showed a reduction in the extent of phosphorylation
of a peptide containing a CDK5-dependent consensus site
396SPVVSGDTSPR406. The fact that the treatment with the
CDK5/GSK3- inhibitors used in this study reduced the phos-
phorylation of Tau as detected byWestern blot, immunohisto-
chemistry, and mass spectrometry provides strong evidence
that the small molecular kinase inhibitor treatment could slow
the progression of Tau pathology. 23-Month-old 3Tg-AD
mice have extensive PHF-1 immunoreactivity. Whether
these immunoreactive inclusions represent neurofibrillary
tangles or some other form of abnormally phosphorylatedTau
is unknown. However, the relatively rapid clearance of the
PHF-1 immunoreactivitywith LDN-193594 treatment suggests
that many of the inclusions in the 3Tg-ADmice at 23months
of age have not aggregated into highly compact and resilient
paired helical filaments but remained exchangeable with a
more soluble Tau compartment (31).
Treatment with LDN-193594 in the CK-p25 mice dramati-
cally affected the prominent neuronal cell loss that accompa-
nies increased CDK5 activity (9). Using NeuN and Fluoro-Jade
as markers, the neuronal loss at 6 weeks of p25 overexpression
was rescued to the level seen in control mice. The fact that the
inhibitor was able to block the accumulation of the fluorescent
PHF-1 signal in the perinuclear area of CA1, while maintaining
the expression pattern of p25-eGFP to a state of early induction
where no cellular loss had yet occurred, argues for a neuropro-
tective effect of the drug (Fig. 3).
Treated mice also improved in a fear-conditioning task. At 6
weeks after induction, CK-p25 mice have accumulated hyper-
phosphorylated Tau with extensive neuronal cell loss and a
severe diminution in memory as measured by two hippocam-
pus-dependent tasks as follows: fear conditioning and theMor-
ris water maze (20). When treated with LDN-193594, CD-p25
mice performed the fear conditioning task as well as the control
mice. The recovery of memory function using this model was
nonpharmacologically demonstrated by restoring memory in
an inducible CDK5 conditional knock-out mouse (40).
The lead compound, LDN-193594, inhibits both GSK3 and
CDK5 nearly equally when tested at the same ATP concentra-
tion. This property of dual kinase inhibition may be related to
its efficacy in these studies.ManyTau residues that are typically
found phosphorylated in insoluble Tau can be phosphorylated
by CDK5 and GSK3. There exists considerable overlap and
cooperation between these two kinases (41). Like CDK5-over-
expressing mice, GSK3-overexpressing mice also display
characteristics typical of AD such as hyperphosphorylation of
Tau as well as learning and memory deficits (38, 42). Effective
therapies for tauopathies such as frontotemporal dementia and
the tauopathy associated with Alzheimer disease may require
inhibition of both kinases.
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